.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Disease Spotlight: NMOSD

EP. 1: Treating NMOSD During COVID-19

October 5th 2021

What to know about treating patients with neuromyelitis optica spectrum disorders throughout the COVID-19 pandemic.

EP. 2: NMOSD Acute Attack Prevention

October 5th 2021

An overview of newer preventive therapies approved for acute attacks of neuromyelitis optica spectrum disorders, and variables that impact treatment selection.

EP. 3: Survey Identifies New Phenotypic Features for Patients With NMOSD in Latin America

September 29th 2021

The study is the first to provide data from all Latin American countries, further identifying geographic-resultant limitations of access to technology and therapy for NMOSD.

EP. 4: Identifying and Managing NMOSD

September 28th 2021

Types of testing that can help neurologists distinguish between acute attacks of neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis, as well as therapies that can be used to help manage patients with NMOSD.

EP. 5: The Guthy-Jackson Charitable Foundation for NMOSD

September 28th 2021

Jacinta M. Behne, MA, describes how the Guthy-Jackson Charitable Foundation supports patients with neuromyelitis optica spectrum disorders.

EP. 6: Eculizumab Provides Long-Term Effective Management of NMOSD

September 26th 2021

Between PREVENT baseline and end, mean EDSS and Hauser Ambulation Index scores improved with eculizumab (Soliris; Alexion) monotherapy and deteriorated with placebo alone.

EP. 7: NMOSD Attack Characteristics and Outcomes Classified by Phenotype, Treatment Option

September 24th 2021

The findings identified Th2-related cytokines as characterizing for the prognosis of acute episodes of NMOSD at 1 month and found serum NfL to be a likely biomarker of disease severity at attack.

EP. 8: NMOSD Relapse Risk Prevalent After Discontinuation of Immunosuppressive Therapy

September 23rd 2021

More than 80% of those with NMOSD experienced disease relapse 6 months after discontinuation of immunosuppressive therapy.

EP. 9: Receiving a Diagnosis of NMOSD

September 21st 2021

Doug and Kim, patients with neuromyelitis optica spectrum disorders, describe the types of symptoms that prompted each of them to seek an evaluation by a neurologist for an eventual diagnosis of a neuromyelitis optica spectrum disorder.

EP. 10: Raising Awareness About NMOSD

September 21st 2021

Mayo Clinic’s Brian G. Weinshenker, MD, compares multiple sclerosis with neuromyelitis optica spectrum disorders (NMOSD) and explains why community neurologists need to receive more education on NMOSD risk factors and symptoms.